Jatinder Mukker
Senior Director & Portfolio Section Head, Quantitative Pharmacology EMD Serono
Seminars
• Highlighting the key reasons DDR programs stall, including weak mechanistic rationale, limited biomarker support, and poor patient stratification
• Presenting real-world case studies from biotech and academia on programs that failed to translate, and the lessons learned
• Exploring how early decisions around target selection, dosing, and trial design impact clinical success
• Identifying practical strategies to improve target validation, including functional assays, predictive biomarkers, and more robust preclinical models
• Evaluating Project Optimus implications for DDR programs and how proactive pharmacological modeling accelerates clinical success
• Highlighting the challenges of dose selection in DDR inhibitor combinations, balancing efficacy with tolerability
• Showcasing how model-based drug development leverages preclinical and clinical data to guide smarter escalation and expansion strategies
